Skip to content
ClinCalc Pro
Menu
Inhalational Analgesic — Procedural Pain Pregnancy: Mild skeletal teratogenic changes have been observed in pregnant rat embryos when the dam has been exposed to high concentrations of nitrous oxide during the period of organogenesis. However, no increased incidence of foetal malformation has been discovered in 8 epidemiological studies and case reports in human beings. There is no published material that shows that nitrous oxide is toxic to the human foetus. Therefore, there is no absolute contra-indication to its use in the first 16 weeks of pregnancy. Lactation: Entonox can be used during the breast-feeding period, but should not be used during breast-feeding itself.

Entonox (Nitrous Oxide 50% / Oxygen 50%)

Brand names: Entonox, Equanox

A ready-mixed inhaled gas of equal parts nitrous oxide and oxygen used as a rapid-onset, short-acting analgesic for procedures such as dressing changes and debridement in burns and plastics.

Adult dose

Dose: Relief of pain (e.g. acute trauma; short-term relief for procedures inevitably involving pain such as wound and burn dressing, wound debridement and suturing): Entonox premixed gas, 50% nitrous oxide / 50% oxygen (SPC section 2: each 50.0% +/- 2.0%), inhaled through a facemask or mouthpiece connected to the cylinder supply via a demand valve system, self-regulated by the patient (in nearly all cases self-administered, but it may be administered by attendant medical personnel)
Route: Inhalation via facemask or mouthpiece and demand valve
Frequency: As required, patient-regulated by the demand valve; not to be used for more than a total of 24 hours, or more frequently than every 4 days, without close clinical supervision and haematological monitoring
The pinned product is ENTONOX MEDICINAL GAS (PL007355017, BOC Ltd), the 50:50 premix, and its §4.1 names the page's use: 'short-term relief for procedures inevitably involving pain, such as wound and burn dressing, wound debridement and suturing'. The brand 'Equanox' is not named in this SPC. §2 (verbatim): 'Oxygen 50.0 % +/- 2.0 % Nitrous Oxide 50.0 % +/- 2.0 %'. §4.1 (verbatim): 'Entonox is used exclusively for the relief of pain.' Examples printed: acute trauma; short-term relief in dental work; procedures inevitably involving pain such as wound and burn dressing, wound debridement and suturing; normal labour; acute surgical or medical conditions in which the pain is relieved only to return on cessation of the analgesia. VERBATIM §4.2: 'Entonox is administered through a facemask or mouthpiece. The facemask or mouthpiece is connected to an Entonox supply through a demand valve system which allows the Entonox to be self-regulated by the patient. The demand valve is operated by the act of inhalation of the patient and closes down when the patient ceases to inhale. In nearly all cases, Entonox is self-administered, but it may be administered by attendant medical personnel. Since pain is usually relieved by a concentration of 25% nitrous oxide, continued inhalation does not occur. However, should inhalation continue, light anaesthesia occurs and the mask or mouthpiece drops away as the patient relaxes, or is removed if administration has been by attendant personnel. There are no contra-indications to the use of Entonox in any age group. Entonox should not be used for more than a total of 24 hours, or more frequently than every 4 days, without close clinical supervision and haematological monitoring.' This is a fixed-composition gas titrated by the patient's own inhalation: the SPC prints no flow rate, volume, onset time or per-session duration, and the only printed use limit is the 24 hours total / every 4 days limit, which is a duration rule and not a dose, so maxDose is left unset. No paediatric block is written: the SPC prints no age-specific dose, minimum age or paediatric technique (§4.2 says only 'There are no contra-indications to the use of Entonox in any age group'; the §4.3 gas-entrapment contraindications still apply). KEY SAFETY (verbatim §4.4): 'Caution should be exercised before using Entonox with patients who have known Chronic Obstructive Pulmonary Disease (COPD) or other conditions where compromised chemoreceptor sensitivity/function may be present' (relatively high oxygen concentration may cause respiratory depression and increases in PaCO2); the use of gases containing more than 21% oxygen should be avoided after exposure to agents toxic to the lungs such as paraquat; waste gas should be scavenged to below 100 ppm; Entonox is non-flammable but strongly supports combustion - no smoking, and no oils or grease on the cylinder or equipment.

Dose adjustments

Renal

No renal dose adjustment is printed in SPC sections 4.2-4.4.

Hepatic

No hepatic dose adjustment is printed in SPC sections 4.2-4.4.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Any condition where gas is entrapped within a body and where its expansion might be dangerous, such as: artificial, traumatic or spontaneous pneumothorax; air embolism; decompression sickness; following a recent dive; following air encephalography; severe bullous emphysema; use during myringoplasty; gross abdominal distension
  • Patients having received a recent intraocular injection of gas (such as SF6)

Side effects

  • Commonly described: euphoria, disorientation, sedation, nausea, vomiting, dizziness and generalised tingling - generally minor and rapidly reversible
  • Listed in the SPC adverse-reaction table: euphoria, dizziness, light-headedness, somnolence, nausea, vomiting, sense of intoxication, feeling of pressure in the middle ear, bloating / increased gas volume in the intestines (the table's frequency columns are not legible in the extracted text, so no frequencies are given)
  • Respiratory depression, generalised seizures, confusion and addiction (also listed in the SPC adverse-reaction table, frequencies not legible in the extracted text)
  • Prolonged or frequent use (including heavy occupational exposure and addiction): megaloblastic anaemia, agranulocytosis after prolonged administration, myeloneuropathy and subacute combined degeneration of the spinal cord
  • Neurological toxicity after a single exposure for anaesthesia in patients with undiagnosed subclinical vitamin B12 deficiency
  • Nitrous oxide passes into gas-containing body spaces faster than nitrogen passes out: prolonged exposure may result in bowel distension, middle ear damage and rupture of ear drums

Interactions

  • Vitamin B12: the nitrous oxide constituent inactivates vitamin B12
  • Methotrexate: the nitrous oxide constituent potentiates its effects on folate metabolism
  • Bleomycin, amiodarone and nitrofurantoin or similar antibiotics: higher levels of oxygen can increase the risk of pulmonary toxicity; give Entonox with caution and at levels kept as low as possible
  • Centrally acting depressants (opiates, benzodiazepines and other psychotropics): additive effects with a risk of pronounced sedation and depression of protective reflexes; use under the supervision of appropriately trained personnel

Monitoring

  • Do not use for more than a total of 24 hours, or more frequently than every 4 days, without close clinical supervision and haematological monitoring; seek specialist advice from a haematologist in such cases
  • Haematological assessment should include megaloblastic change in red cells and hypersegmentation of neutrophils; neurological toxicity can occur without anaemia or macrocytosis and with B12 levels in the normal range
  • Caution in patients with known COPD or other conditions with compromised chemoreceptor sensitivity/function (respiratory depression and a rise in PaCO2 possible)
  • Caution in patients with a known history of substance abuse (repeated administration may lead to addiction)
  • Scavenge waste gas to keep ambient nitrous oxide below 100 ppm in theatre and equivalent treatment rooms

Clinical monograph

How it works

Inhaled nitrous oxide produces analgesia and light sedation through central effects including modulation of opioid and NMDA-receptor pathways, while the oxygen component maintains oxygenation.

Prescribing in practice

  • It is contraindicated where gas can expand in trapped spaces, including pneumothorax, bowel obstruction and recent intraocular or middle-ear surgery and decompression illness.
  • Prolonged or repeated exposure can inactivate vitamin B12 and impair folate metabolism, causing neurological and haematological harm, so cumulative use should be limited.
  • Adequate room scavenging and ventilation are needed to protect staff from chronic exposure.

Monitoring

Monitor conscious level and adequacy of analgesia during use; the short half-life means recovery is rapid once inhalation stops.

Counselling the patient

  • Breathe the gas through the mouthpiece during the painful part of the procedure.
  • It works quickly and wears off within minutes of stopping.
  • Tell staff if you feel very lightheaded, sick or unwell.

Evidence & guidelines

Entonox is a long-established inhaled analgesic for short painful procedures, with MHRA cautions regarding gas-filled spaces and vitamin B12 effects from repeated exposure.

Reference: AAGBI/Faculty of Pain Medicine Entonox Guidelines; BBA Burns Dressing Change Analgesia Protocol; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.